FARALLON CAPITAL MANAGEMENT LLC - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 396 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.80 and the average weighting 0.3%.

Quarter-by-quarter ownership
FARALLON CAPITAL MANAGEMENT LLC ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$166,701,744
+20.8%
1,375,200
+14.1%
0.84%
+16.6%
Q2 2023$138,019,504
+9.6%
1,205,200
+32.0%
0.72%
+3.0%
Q1 2023$125,880,139
+4.6%
913,300
-1.7%
0.70%
-3.1%
Q4 2022$120,366,862
+44.2%
928,900
+23.0%
0.72%
+55.4%
Q3 2022$83,452,000
-6.1%
754,950
-36.3%
0.46%
-4.7%
Q2 2022$88,831,000
+14.6%
1,185,051
+19.5%
0.48%
+29.7%
Q1 2022$77,493,000
+2.6%
991,975
+18.2%
0.37%
-0.8%
Q4 2021$75,553,000
+404.3%
839,009
+417.9%
0.38%
+438.6%
Q3 2021$14,982,000
-33.0%
162,000
-46.0%
0.07%
-36.9%
Q1 2021$22,359,000
-78.1%
300,000
-50.0%
0.11%
-82.0%
Q4 2020$102,294,000
+21.4%
600,0000.0%0.62%
+5.5%
Q3 2020$84,258,000
+0.1%
600,000
+14.3%
0.58%
-13.5%
Q2 2020$84,179,000
+145.9%
525,000
+50.0%
0.67%
+129.3%
Q1 2020$34,237,000
-33.7%
350,000
-12.5%
0.29%
-15.5%
Q4 2019$51,616,000
-32.1%
400,000
-20.0%
0.35%
-29.6%
Q2 2019$75,975,000
-1.9%
500,000
-23.1%
0.49%
-15.3%
Q1 2019$77,474,000
+10.9%
650,000
+1.6%
0.58%
+13.9%
Q4 2018$69,843,000
+121.8%
640,000
+228.2%
0.51%
+175.3%
Q3 2018$31,494,000195,0000.19%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Casdin Capital, LLC 1,010,330$122,472,20313.56%
Finepoint Capital LP 145,357$17,620,1768.78%
Avoro Capital Advisors LLC 4,025,000$487,910,5007.61%
Saturn V Capital Management LP 118,401$14,352,5696.01%
Ghost Tree Capital, LLC 150,000$18,183,0005.98%
Ikarian Capital, LLC 3,673$44,524,1065.36%
ACUTA CAPITAL PARTNERS, LLC 550$7,580,6505.08%
Eagle Health Investments LP 174,212$21,117,9794.65%
Boxer Capital, LLC 600,000$72,732,0003.87%
GREAT POINT PARTNERS LLC 165,200$20,025,5443.65%
View complete list of SAREPTA THERAPEUTICS INC shareholders